Never miss the latest news and offers - subscribe now!
How an integrated manufacturing solution can address the current capacity constraints for viral vector manufacturing
Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.
Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.
Participants will learn:
Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Notice